Expansion of access begins with simple conversations.
Starting tomorrow, from 6–8 October, the Biocon team will be on the ground at Fiera Milano, ready to discuss our established capabilities in biosimilars, complex APIs, and global-scale manufacturing.
If you are looking for a reliable, long-term execution partner to help navigate the future of healthcare, we invite you to visit us.
Meet us at Stand 7D34 to explore how our capabilities and global scale can support your ambitions. Let’s have a conversation.
#biocon #cphimilan2026 #pharmamanufacturing #biosimilars #patientaccess #globalscale #healthcarepartnerships
Biocon continued to make good progress on its strategic priorities in Q2 and H1 FY27 driven by new business wins, regulatory approvals and new product launches across its Biopharma business.
Q2 highlights
• Consolidated operating revenue increased 2% YoY to Rs 4,389 crore.
• Biopharma revenue increased 5% YoY to Rs 3,583 crore.
H1 highlights
• Consolidated operating revenue increased 6% YoY to Rs 8,725 crore.
• Biopharma revenue increased 11% YoY to Rs 7,200 crore.
• Net profit increased by 57% YoY to Rs 182 crore.
Read more at www.biocon.com/biocon-q2fy27-revenue/
#q2fy27 #h1fy27

































































































































































































































































































































































































































































































































































































































































































































































































